La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Hepion Pharmaceuticals Gestione

Gestione criteri di controllo 3/4

Hepion Pharmaceuticals' Il CEO è John Brancaccio, nominato in Aug2024, ha un mandato di 11.25 anni. possiede direttamente 0.006% delle azioni della società, per un valore di $ 276.33. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 4.8 anni e 1.8 anni.

Informazioni chiave

John Brancaccio

Amministratore delegato

US$81.0k

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	no data
Proprietà del CEO	0.006%
Durata media del management	4.8yrs
Durata media del Consiglio di amministrazione	1.8yrs

Aggiornamenti recenti sulla gestione

Recent updates

Additional Phase IIa Data Confirms Hepion's CRV431 As A Very Promising NASH Candidate Drug

Sep 21

Companies Like Hepion Pharmaceuticals (NASDAQ:HEPA) Are In A Position To Invest In Growth

Sep 14

Hepion Pharmaceuticals: A Promising Early-Stage Biopharma In The NASH Race

Sep 08

Treating Chronic Liver Disease - Interview With Hepion Pharmaceuticals CEO Dr. Robert Foster (Video)

May 26

What Type Of Shareholders Make Up Hepion Pharmaceuticals, Inc.'s (NASDAQ:HEPA) Share Registry?

Feb 18

Hepion Pharma cleared to advance final dosing cohort in NASH trial

Dec 29

Hepion Pharma to begin CRV431 testing in COVID-19 patients

Dec 22

Dosing underway in higher dose cohort with Hepion's CRV431 in NASH study

Dec 10

Hepion Pharma prices equity offering at $1.50

Nov 25

Hepion Pharmaceuticals (HEPA) Investor Presentation - Slideshow

Oct 31

AMMINISTRATORE DELEGATO

John Brancaccio (76 yo)

no data

Mandato

US$81,000

Compensazione

Mr. John Patrick Brancaccio, C.P.A, serves as Independent Non-Executive Director at Tiziana Life Sciences plc since July 2020. He is an Independent Non-Executive Director at OKYO Pharma Limited since June...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
John Brancaccio	Interim CEO	no data	US$81.00k	0.0060% $ 266.6
Sharen Pyatetskaya	Director of Investor Relations	no data	Nessun dato	Nessun dato
John Sullivan-Bolyai	Part-Time Consultant	6.7yrs	US$34.62k	Nessun dato
Stephen A. Harrison	Scientific Advisory Board Chair & Consultant Medical Director	4.8yrs	Nessun dato	Nessun dato

4.8yrs

Durata media

Gestione esperta: Il team dirigenziale di HEPA è considerato esperto (durata media dell'incarico 4.8 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
John Brancaccio	Interim CEO	11.3yrs	US$81.00k	0.0060% $ 266.6
Stephen A. Harrison	Scientific Advisory Board Chair & Consultant Medical Director	5yrs	Nessun dato	Nessun dato
Timothy M. Block	Independent Director	10.8yrs	US$72.90k	0.0060% $ 266.6
Vlad Raziu	Member of Scientific Advisory Board	1.4yrs	Nessun dato	Nessun dato
Rohit Loomba	Member of Scientific Advisory Board	1.4yrs	Nessun dato	Nessun dato
Nikolai Naoumov	Member of Scientific Advisory Board	1.4yrs	Nessun dato	Nessun dato
Philippe Gallay	Member of Scientific Advisory Board	8.1yrs	Nessun dato	Nessun dato
Michael Purcell	Independent Director	less than a year	Nessun dato	Nessun dato
Yury Popov	Member of Scientific Advisory Board	1.4yrs	Nessun dato	Nessun dato
Kaouthar Lbiati	Independent Director	2.2yrs	US$80.50k	Nessun dato
Vlad Ratziu	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato

1.8yrs

Durata media

68yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di HEPA non è considerato esperto (durata media del mandato 1.8 anni), il che suggerisce un nuovo consiglio.

Hepion Pharmaceuticals Gestione

Gestione criteri di controllo 3/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

High number of new and inexperienced directors

Hepion Pharmaceuticals, Inc. Appoints Michael Purcell to Its Board of Directors

High number of new and inexperienced directors

Hepion Pharmaceuticals, Inc. Announces Resignation of Anand Reddi from the Board of Directors

Hepion Pharmaceuticals, Inc. Announces CEO Changes

Hepion Pharmaceuticals, Inc. Announces Resignation of Dr. Todd Hobbs, as the Chief Medical Officer, Effective September 29, 2023

Recent updates

High number of new and inexperienced directors

Pharma Two B Ltd. agreed to acquire Hepion Pharmaceuticals, Inc. (NasdaqCM:HEPA) in a reverse merger transaction valued at an implied equity value of approximately $58.5 million.

Hepion Pharmaceuticals, Inc. announced delayed 10-Q filing

Hepion Pharmaceuticals, Inc. Initiates Wind-Down Activities in Phase 2b ‘ASCEND-NASH’ Trial

Hepion Pharmaceuticals, Inc. announced delayed annual 10-K filing

Hepion Pharmaceuticals, Inc. Appoints Michael Purcell to Its Board of Directors

New major risk - Share price stability

Price target decreased by 27% to US$30.00

High number of new and inexperienced directors

Hepion Pharmaceuticals, Inc. Announces Resignation of Anand Reddi from the Board of Directors

Hepion Pharmaceuticals, Inc. Announces CEO Changes

Hepion Pharmaceuticals, Inc. announced delayed 10-Q filing

Hepion Pharmaceuticals Announces Major Reductions in Liver Stiffness with Rencofilstat Treatment in 17-Week Phase 2 Study of Advanced (F3) Mash Liver Disease

New minor risk - Share price stability

Hepion Pharmaceuticals, Inc. Announces the Publication of New Research Study in Mice

New minor risk - Shareholder dilution

Hepion Pharmaceuticals, Inc. announced that it has received $5.000004 million in funding

Price target decreased by 46% to US$23.67

Hepion Pharmaceuticals, Inc. Announces Results from A Study with in Which the Anti-Cancer Activity of Hepion's Lead Drug Candidate, Rencofilstat

Hepion Pharmaceuticals, Inc. Announces Positive Results from Translational Research Study

Hepion Pharmaceuticals, Inc. Announces Resignation of Dr. Todd Hobbs, as the Chief Medical Officer, Effective September 29, 2023

New major risk - Financial position

Hepion Pharmaceuticals (NASDAQ:HEPA) Will Have To Spend Its Cash Wisely

New major risk - Financial position

Hepion Pharmaceuticals Announces Passing of Key Safety Milestone in Phase 2b ‘ASCEND-NASH’ Trial of Rencofilstat

Hepion Pharmaceuticals, Inc. Announces Positive Topline Results from Its Recently Completed Phase 2 Altitude-Nash Clinical Trial

Price target decreased by 10% to US$62.67

High number of new directors

We're Keeping An Eye On Hepion Pharmaceuticals' (NASDAQ:HEPA) Cash Burn Rate

Hepion Pharmaceuticals, Inc. Announces Positive Results of Preclinical Studies Examining Rencofilstat as A Potential Therapeutic for Multiple Myeloma

Hepion Pharmaceuticals, Inc. Presents of Preclinical Study Highlighting Anti-Cancer Activity of Rencofilstat in Combination with Proteosome Inhibitors

Hepion Pharmaceuticals Receives 180-Day Extension by Nasdaq to Meet the Minimum Bid Price Requirements

Hepion Pharmaceuticals Announces Early Completion of Enrollment in Phase 2 'Altitude-Nash' Liver Function Trial

Price target decreased to US$2.50

Hepion Pharmaceuticals, Inc. Announces Publication of Phase 2A 'Ambition' Clinical Trial Results

We're Keeping An Eye On Hepion Pharmaceuticals' (NASDAQ:HEPA) Cash Burn Rate

Hepion Pharmaceuticals, Inc. Announces Initiation of Dosing in Phase 2 'ALTITUDE-NASH' Liver Function Trial

Hepion Pharmaceuticals, Inc. Announces Initiation of Phase 2b ‘ASCEND-NASH’ Trial

Hepion Pharma rises as company begins NASH treatment trial

Hepion Pharmaceuticals, Inc., Annual General Meeting, Aug 05, 2022

Will Hepion Pharmaceuticals (NASDAQ:HEPA) Spend Its Cash Wisely?

Price target decreased to US$4.75

Hepion Pharmaceuticals, Inc. Announces Board Changes

Hepion Pharmaceuticals, Inc. Appoints Dr. Launa J. Aspeslet as Chief Operating Officer

Hepion Pharmaceuticals Receives Notice of Delisting or Failure to Satisfy Continued Listing Rule or Standard from Nasdaq

Hepion Pharmaceuticals Announces Clinical Collaboration with HepQuant in Phase 2b NASH Trial

Hepion Pharmaceuticals, Inc., Annual General Meeting, Jun 24, 2022

Hepion Pharmaceuticals, Inc. announced delayed annual 10-K filing

Hepion Pharmaceuticals CEO Robert Foster - Dash To Beat NASH

Hepion Pharmaceuticals Appoints Eddie C. Cheung to Lead the Company’s Strategic Medical Affairs in Asia

Hepion Pharmaceuticals: Facing The Momentous Year 2022

Hepion Pharmaceuticals Announces FDA Clearance of IND Application for CRV431 in the Treatment of Liver Cancer

Additional Phase IIa Data Confirms Hepion's CRV431 As A Very Promising NASH Candidate Drug

Hepion Pharmaceuticals, Inc Announces Additional Efficacy Data from Its Phase 2A Ambition Clinical Trial

Companies Like Hepion Pharmaceuticals (NASDAQ:HEPA) Are In A Position To Invest In Growth

Hepion Pharmaceuticals: A Promising Early-Stage Biopharma In The NASH Race

Hepion Pharmaceuticals, Inc. Announces Positive Topline Data from Phase 2A ‘Ambition’ Nash Trial and Achieve All Primary Endpoints

Treating Chronic Liver Disease - Interview With Hepion Pharmaceuticals CEO Dr. Robert Foster (Video)

Hepion Pharmaceuticals Completes Final Patient Recruitment in Phase 2A 'AMBITION' Clinical Trial of CRV431 for the Treatment of Advanced NASH

Hepion Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $88.4 million.

What Type Of Shareholders Make Up Hepion Pharmaceuticals, Inc.'s (NASDAQ:HEPA) Share Registry?

Todd M. Hobbs, Joins Hepion Pharmaceuticals as Chief Medical Officer

New 90-day high: US$2.98

Hepion Pharmaceuticals Data Safety Monitoring Board Recommends Continuation with Final Dose Cohort in Phase 2a 'AMBITION' Clinical Trial for Treatment of Advanced NASH

Hepion Pharma cleared to advance final dosing cohort in NASH trial

Hepion Pharma to begin CRV431 testing in COVID-19 patients

Dosing underway in higher dose cohort with Hepion's CRV431 in NASH study

Hepion Pharmaceuticals’ CRV431 Demonstrates Additional Potential Advantage in Liver Disease

Hepion Pharmaceuticals, Inc. has completed a Follow-on Equity Offering.